Vamil Divan
Stock Analyst at Guggenheim
(4.78)
# 125
Out of 5,031 analysts
236
Total ratings
67.26%
Success rate
20.79%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Upgrades: Buy | $167 → $206 | $193.22 | +6.61% | 17 | Sep 23, 2025 | |
| SVRA Savara | Maintains: Buy | $8 → $11 | $3.61 | +204.71% | 2 | Sep 9, 2025 | |
| VALN Valneva SE | Maintains: Buy | $14 → $13 | $10.04 | +29.48% | 2 | Sep 8, 2025 | |
| ANIP ANI Pharmaceuticals | Maintains: Buy | $86 → $114 | $94.79 | +20.27% | 12 | Sep 8, 2025 | |
| INSM Insmed | Maintains: Buy | $125 → $172 | $165.76 | +3.76% | 7 | Sep 8, 2025 | |
| ASMB Assembly Biosciences | Maintains: Buy | $31 → $39 | $29.45 | +32.43% | 2 | Sep 8, 2025 | |
| ABBV AbbVie | Maintains: Buy | $216 → $227 | $229.57 | -1.12% | 27 | Aug 1, 2025 | |
| PROK ProKidney | Maintains: Buy | $6 → $7 | $2.97 | +135.69% | 2 | Jul 14, 2025 | |
| JBIO Jade Biosciences | Upgrades: Buy | $14 | $9.37 | +49.41% | 1 | Jun 16, 2025 | |
| AMGN Amgen | Assumes: Neutral | $288 | $298.81 | -3.62% | 1 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $4.71 | +1,173.89% | 1 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $115 | $84.79 | +35.63% | 14 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $47 | $27.32 | +72.04% | 8 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $4.53 | +120.75% | 3 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $24.51 | - | 22 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $59 → $61 | $31.23 | +95.33% | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $13.83 | - | 5 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $2.01 | +1,193.53% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $9 | $0.75 | +1,092.68% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.19 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $20.89 | -9.05% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $140.09 | -30.04% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $30.26 | +12.36% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $2.85 | +250.88% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $127.94 | -61.70% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $802.83 | -55.66% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $9.24 | -35.06% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $15.95 | +865.52% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $6.40 | +134.38% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $34.51 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $19.31 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $7.04 | +113.07% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $43.63 | +39.81% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $2.75 | +3,645.45% | 3 | Jan 17, 2018 |
Johnson & Johnson
Sep 23, 2025
Upgrades: Buy
Price Target: $167 → $206
Current: $193.22
Upside: +6.61%
Savara
Sep 9, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $3.61
Upside: +204.71%
Valneva SE
Sep 8, 2025
Maintains: Buy
Price Target: $14 → $13
Current: $10.04
Upside: +29.48%
ANI Pharmaceuticals
Sep 8, 2025
Maintains: Buy
Price Target: $86 → $114
Current: $94.79
Upside: +20.27%
Insmed
Sep 8, 2025
Maintains: Buy
Price Target: $125 → $172
Current: $165.76
Upside: +3.76%
Assembly Biosciences
Sep 8, 2025
Maintains: Buy
Price Target: $31 → $39
Current: $29.45
Upside: +32.43%
AbbVie
Aug 1, 2025
Maintains: Buy
Price Target: $216 → $227
Current: $229.57
Upside: -1.12%
ProKidney
Jul 14, 2025
Maintains: Buy
Price Target: $6 → $7
Current: $2.97
Upside: +135.69%
Jade Biosciences
Jun 16, 2025
Upgrades: Buy
Price Target: $14
Current: $9.37
Upside: +49.41%
Amgen
May 20, 2025
Assumes: Neutral
Price Target: $288
Current: $298.81
Upside: -3.62%
Apr 21, 2025
Initiates: Buy
Price Target: $60
Current: $4.71
Upside: +1,173.89%
Apr 17, 2025
Reiterates: Buy
Price Target: $115
Current: $84.79
Upside: +35.63%
Apr 14, 2025
Reiterates: Buy
Price Target: $47
Current: $27.32
Upside: +72.04%
Mar 20, 2025
Reiterates: Buy
Price Target: $10
Current: $4.53
Upside: +120.75%
Mar 18, 2025
Reiterates: Buy
Price Target: n/a
Current: $24.51
Upside: -
Feb 27, 2025
Maintains: Buy
Price Target: $59 → $61
Current: $31.23
Upside: +95.33%
Jan 17, 2025
Reiterates: Neutral
Price Target: n/a
Current: $13.83
Upside: -
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $2.01
Upside: +1,193.53%
Apr 3, 2023
Maintains: Buy
Price Target: $8 → $9
Current: $0.75
Upside: +1,092.68%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $2.19
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $20.89
Upside: -9.05%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $140.09
Upside: -30.04%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $30.26
Upside: +12.36%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $2.85
Upside: +250.88%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $127.94
Upside: -61.70%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $802.83
Upside: -55.66%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $9.24
Upside: -35.06%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $15.95
Upside: +865.52%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $6.40
Upside: +134.38%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $34.51
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $19.31
Upside: -
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $7.04
Upside: +113.07%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $43.63
Upside: +39.81%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $2.75
Upside: +3,645.45%